top of page
News, Events and Updates
Search
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
Feb 1, 2024
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX® 3-71 in Humans
Jan 24, 2024
Anavex Life Sciences Announces U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Jan 16, 2024
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
Jan 8, 2024
Anavex to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Jan 3, 2024
Anavex Life Sciences Provides an Update on Rett Syndrome Program
Jan 2, 2024
Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX®2-73 from AVATAR Study in Patients with Rett Syndrome
Dec 20, 2023
Anavex Received Agreement from the Committee for Medicinal Products for Human Use (CHMP)
Dec 19, 2023
Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update
Nov 27, 2023
Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023
Nov 24, 2023
Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73)
Nov 22, 2023
2
3
4
5
6
Stay Connected
Follow us on social media
Newsroom
Webcast Library
Contact Us
Back to Newsroom
bottom of page
